ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
부트리시란 시장 규모는 향후 수년간 급성장할 것으로 전망됩니다. 2029년에는 CAGR 12.0%를 나타내 10억 6,000만 달러로 성장할 전망입니다. 예측 기간의 성장은 건강관리의 가용성 증가, 만성질환의 유병률 증가, 연구개발 투자 증가, 맞춤형 의료에 대한 관심 증가, 질병에 대한 의식 증가로 인한 것으로 예측됩니다. 예측 기간의 주요 동향으로는 병용요법의 개발, 표적요법의 채용, 맞춤형 의료의 진전, 디지털 헬스 기술의 개발, 생명공학의 진전 등을 들 수 있습니다.
향후 5년간의 성장률 12.0%라고 하는 예측은 이 시장의 전회 예측으로부터 0.4%의 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세 인상은 네덜란드에서 생산되는 RNAi 치료제와 유전성 트랜스사이레틴 아밀로이드증 치료제의 비용을 증가시키고 노인 환자의 진행성 다발신경염 관리를 위태롭게 하기 때문에 미국 신경과에 지장을 줄 수 있습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.
연구개발에 대한 투자 증가는 앞으로 수년간 부트리시란 시장 성장을 가속할 것으로 예측됩니다. 연구개발은 체계적인 조사와 실험을 통해 제품, 서비스, 프로세스를 혁신·강화하는 것입니다. R&D 투자 증가는 정부의 이니셔티브와 자금 제공, 의료 및 의약품 수요 증가, 지속가능성에 대한 노력, 환경 우려에 기인합니다. 연구개발에 대한 자금제공으로 제약기업은 임상시험을 실시하고 의약품의 장기적인 효능과 안전성을 입증하며 보다 폭넓은 규제당국의 승인으로 이어질 수 있습니다. 게다가, RNA 간섭(RNAi) 기술의 진보는 약물의 정확성을 향상시키고, 부작용을 최소화하고, 환자에게의 보급을 추진합니다. 예를 들어, 2023년 12월, 룩셈부르크에 본사를 둔 유럽연합(EU)의 통계국인 유로스타트는 EU의 연구개발비가 2022년에 3,520억 유로(3,844억 2,000만 달러)에 이르렀고, 전년 3,310억 유로(3,614억 8,000만 달러)에서 6.34% 증가했다고 보고했습니다. 그 결과, R&D 투자 증가가 부트리시란 시장 확대에 박차를 가하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 부트리시란 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 부트리시란 시장 : 성장률 분석
세계의 부트리시란 시장 실적 : 규모와 성장(2019-2024년)
세계의 부트리시란 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 부트리시란 : 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 부트리시란 시장 : 약제 클래스별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
안티센스 올리고뉴클레오티드
핵산
뉴클레오티드
뉴클레오사이드
기타 약제 클래스
세계의 부트리시란 시장 : 투여 경로별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
경구
주사제
피하
세계의 부트리시란 시장 : 환자 인구 통계별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
소아
성인
노인
세계의 부트리시란 시장 : 유통 채널별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원 약국
소매 약국
온라인 약국
기타 유통 채널
세계의 부트리시란 시장 : 안티센스 올리고뉴클레오티드 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
단일 가닥 안티센스 올리고뉴클레오티드
이중 가닥 안티센스 올리고뉴클레오티드
세계의 부트리시란 시장 : 핵산 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
DNA 기반 핵산
RNA 기반 핵산
세계의 부트리시란 시장 : 뉴클레오티드 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
퓨린 뉴클레오티드
피리미딘 뉴클레오티드
세계의 부트리시란 시장 : 뉴클레오사이드 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
퓨린 뉴클레오사이드
피리미딘 뉴클레오사이드
세계의 부트리시란 시장 : 기타 약제 클래스 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
펩타이드 기반 약물
단백질 치료제
제7장 지역별/국가별 분석
세계의 부트리시란 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 부트리시란 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
부트리시란 시장 : 경쟁 구도
부트리시란 시장 : 기업 프로파일
Alnylam Pharmaceuticals Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 세계 시장 경쟁 벤치마킹과 대시보드
제32장 주요 인수합병(M&A)
제33장 최근 시장 동향
제34장 시장의 잠재력이 높은 국가, 부문, 전략
부트리시란 시장(2029년) : 새로운 기회를 제공하는 국가
부트리시란 시장(2029년) : 새로운 기회를 제공하는 부문
부트리시란 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제35장 부록
KTH
영문 목차
영문목차
Vutrisiran is a small interfering RNA (siRNA) therapy used to treat hereditary transthyretin-mediated (hATTR) amyloidosis. It works by silencing the transthyretin (TTR) gene, reducing abnormal TTR protein deposits responsible for polyneuropathy and organ damage. Vutrisiran helps slow disease progression while improving neurological function, mobility, and overall quality of life, offering the benefit of a longer dosing interval.
The primary drug classes for vutrisiran include antisense oligonucleotides, nucleic acids, nucleotides, nucleosides, and others. Antisense oligonucleotides (ASOs) are synthetic short DNA or RNA molecules designed to target specific mRNA sequences and regulate gene expression. Vutrisiran is administered through various routes, including oral, injectable, and subcutaneous, and is suitable for different patient demographics, including pediatric, adult, and geriatric populations. It is distributed through multiple channels, such as hospital pharmacies, retail pharmacies, online pharmacies, and others.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment-many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.
The vutrisiran market research report is one of a series of new reports from The Business Research Company that provides vutrisiran market statistics, including the vutrisiran industry global market size, regional shares, competitors with the vutrisiran market share, detailed vutrisiran market segments, market trends, and opportunities, and any further data you may need to thrive in the vutrisiran industry. This vutrisiran market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The vutrisiran market size has grown rapidly in recent years. It will grow from $0.6 billion in 2024 to $0.67 billion in 2025 at a compound annual growth rate (CAGR) of 11.8%. The growth in the historic period can be attributed to increasing awareness of hereditary transthyretin amyloidosis, rising clinical trials, increasing healthcare spending, rising patient preference for non-invasive administration methods, and rising genetic disorders.
The vutrisiran market size is expected to see rapid growth in the next few years. It will grow to $1.06 billion in 2029 at a compound annual growth rate (CAGR) of 12.0%. The growth in the forecast period can be attributed to increasing healthcare availability, rising prevalence of chronic diseases, increasing investment in research and development, growing focus on personalized medicine, and rising awareness of disease. Major trends in the forecast period include development in combination therapy, adoption of targeted therapy, advancement in personalized medicine, development in digital health technologies, and advancements in biotechnology.
The forecast of 12.0% growth over the next five years reflects a modest reduction of 0.4% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff increases could hinder U.S. neurology departments by inflating costs of RNAi therapeutics and hereditary transthyretin amyloidosis treatments manufactured in the Netherlands, compromising management of progressive polyneuropathy in elderly patients. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The increasing investment in research and development is expected to drive the growth of the vutrisiran market in the coming years. Research and development involve innovating and enhancing products, services, or processes through systematic investigation and experimentation. The rise in R&D investment is attributed to government initiatives and funding, increasing healthcare and pharmaceutical demands, sustainability efforts, and environmental concerns. Funding for research and development enables pharmaceutical companies to conduct clinical trials, demonstrating the drug's long-term efficacy and safety, leading to wider regulatory approvals. Additionally, advancements in RNA interference (RNAi) technology enhance the drug's precision, minimizing side effects and increasing patient adoption. For example, in December 2023, Eurostat, a Luxembourg-based statistical office of the European Union, reported that the European Union's research and development expenditure reached €352 billion ($384.42 billion) in 2022, reflecting a 6.34% increase from €331 billion ($361.48 billion) in the previous year. As a result, rising investments in research and development are fueling the expansion of the vutrisiran market.
Companies operating in the vutrisiran market are focusing on developing innovative treatments, such as subcutaneous RNAi therapeutics, to offer more convenient and less frequent dosing options for managing hereditary transthyretin-mediated (hATTR) amyloidosis. These therapeutics utilize RNA interference technology and are administered through injections under the skin, ensuring sustained drug release. This approach maintains consistent drug levels over time, enhancing patient convenience and adherence in treating polyneuropathy associated with hereditary transthyretin-mediated (hATTR) amyloidosis. For example, in June 2022, Alnylam Pharmaceuticals, a US-based biopharmaceutical company, announced that vutrisiran (AMVUTTRA) received approval from the Food and Drug Administration (FDA) for the treatment of polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis. The drug significantly alleviates neuropathy symptoms and slows disease progression. In the HELIOS-A Phase 3 study, more than 50% of patients showed a reversal or halt in disease manifestations. AMVUTTRA has demonstrated a favorable safety profile, with no drug-related discontinuations or fatalities, and features a dosing regimen that may enhance patient compliance.
In April 2024, Medison Pharma, an Israel-based pharmaceutical company, collaborated with Alnylam Pharmaceuticals Inc. to extend the commercialization of RNAi therapeutics. This partnership seeks to increase global availability of Alnylam's innovative RNAi treatments, particularly for patients with rare diseases, by leveraging Medison's integrated commercialization platform across multiple regions, including LATAM, APAC, and other international markets. Alnylam Pharmaceuticals, Inc. is a US-based pharmaceutical company that manufactures vutrisiran.
The key player in the vutrisiran market is Alnylam Pharmaceuticals Inc.
North America was the largest region in the vutrisiran market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in vutrisiran report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the vutrisiran market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The vutrisiran market consists of sales of pre-filled syringes and vials for subcutaneous injection. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Vutrisiran Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on vutrisiran market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for vutrisiran ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The vutrisiran market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Drug Class: Antisense Oligonucleotide; Nucleic Acids; Nucleotide; Nucleoside; Other Drug Classes
2) By Route Of Administration: Oral; Injectable; Subcutaneous
3) By Patient Demographics: Pediatric; Adult; Geriatric
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
Subsegments:
1) By Antisense Oligonucleotide: Single-Stranded Antisense Oligonucleotides; Double-Stranded Antisense Oligonucleotides
2) By Nucleic Acids: DNA-based Nucleic Acids; RNA-based Nucleic Acids
3) By Nucleotide: Purine Nucleotides; Pyrimidine Nucleotides
4) By Nucleoside: Purine Nucleosides; Pyrimidine Nucleosides
5) By Other Drug Classes: Peptide-Based Drugs; Protein Therapeutics
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Vutrisiran Market Characteristics
3. Vutrisiran Market Trends And Strategies
4. Vutrisiran Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Vutrisiran Growth Analysis And Strategic Analysis Framework
5.1. Global Vutrisiran PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Vutrisiran Market Growth Rate Analysis
5.4. Global Vutrisiran Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Vutrisiran Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Vutrisiran Total Addressable Market (TAM)
6. Vutrisiran Market Segmentation
6.1. Global Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Antisense Oligonucleotide
Nucleic Acids
Nucleotide
Nucleoside
Other Drug Classes
6.2. Global Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Injectable
Subcutaneous
6.3. Global Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pediatric
Adult
Geriatric
6.4. Global Vutrisiran Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Other Distribution Channels
6.5. Global Vutrisiran Market, Sub-Segmentation Of Antisense Oligonucleotide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Single-Stranded Antisense Oligonucleotides
Double-Stranded Antisense Oligonucleotides
6.6. Global Vutrisiran Market, Sub-Segmentation Of Nucleic Acids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
DNA-based Nucleic Acids
RNA-based Nucleic Acids
6.7. Global Vutrisiran Market, Sub-Segmentation Of Nucleotide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Purine Nucleotides
Pyrimidine Nucleotides
6.8. Global Vutrisiran Market, Sub-Segmentation Of Nucleoside, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Purine Nucleosides
Pyrimidine Nucleosides
6.9. Global Vutrisiran Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Peptide-Based Drugs
Protein Therapeutics
7. Vutrisiran Market Regional And Country Analysis
7.1. Global Vutrisiran Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Vutrisiran Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Vutrisiran Market
8.1. Asia-Pacific Vutrisiran Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Vutrisiran Market
9.1. China Vutrisiran Market Overview
9.2. China Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Vutrisiran Market
10.1. India Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Vutrisiran Market
11.1. Japan Vutrisiran Market Overview
11.2. Japan Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Vutrisiran Market
12.1. Australia Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Vutrisiran Market
13.1. Indonesia Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Vutrisiran Market
14.1. South Korea Vutrisiran Market Overview
14.2. South Korea Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Vutrisiran Market
15.1. Western Europe Vutrisiran Market Overview
15.2. Western Europe Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Vutrisiran Market
16.1. UK Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Vutrisiran Market
17.1. Germany Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Vutrisiran Market
18.1. France Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Vutrisiran Market
19.1. Italy Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Vutrisiran Market
20.1. Spain Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Vutrisiran Market
21.1. Eastern Europe Vutrisiran Market Overview
21.2. Eastern Europe Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Vutrisiran Market
22.1. Russia Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Vutrisiran Market
23.1. North America Vutrisiran Market Overview
23.2. North America Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Vutrisiran Market
24.1. USA Vutrisiran Market Overview
24.2. USA Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Vutrisiran Market
25.1. Canada Vutrisiran Market Overview
25.2. Canada Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Vutrisiran Market
26.1. South America Vutrisiran Market Overview
26.2. South America Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Vutrisiran Market
27.1. Brazil Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Vutrisiran Market
28.1. Middle East Vutrisiran Market Overview
28.2. Middle East Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Vutrisiran Market
29.1. Africa Vutrisiran Market Overview
29.2. Africa Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Vutrisiran Market Competitive Landscape And Company Profiles
30.1. Vutrisiran Market Competitive Landscape
30.2. Vutrisiran Market Company Profiles
30.2.1. Alnylam Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
31. Global Vutrisiran Market Competitive Benchmarking And Dashboard
32. Key Mergers And Acquisitions In The Vutrisiran Market
33. Recent Developments In The Vutrisiran Market
34. Vutrisiran Market High Potential Countries, Segments and Strategies
34.1 Vutrisiran Market In 2029 - Countries Offering Most New Opportunities
34.2 Vutrisiran Market In 2029 - Segments Offering Most New Opportunities
34.3 Vutrisiran Market In 2029 - Growth Strategies
34.3.1 Market Trend Based Strategies
34.3.2 Competitor Strategies
35. Appendix
35.1. Abbreviations
35.2. Currencies
35.3. Historic And Forecast Inflation Rates
35.4. Research Inquiries
35.5. The Business Research Company
35.6. Copyright And Disclaimer
(주)글로벌인포메이션02-2025-2992kr-info@giikorea.co.kr ⓒ Copyright Global Information, Inc. All rights reserved.
